1. Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: Cancer drug discovery and development program. Semin Oncol. 1992;19:622–38.
2. Law LW, Dunn TB, Boyle PJ, Miller JH. Observations on the effect of a folic-acid antagonist on transplantable lymphoid leukemias in mice. J Natl Cancer Inst. 1949;10:179–92.
3. Dawe CJ, Potter M. Morphologic and biological progression of a lymphoid neoplasm of the mouse in vivo and in vitro (abstr). Am J Pathol. 1957;33:603.
4. Teicher BA. In vivo tumor response end points. In: Teicher BA, editor. Tumor models in cancer research. Totowa, NJ: Humana Press. 2002. p. 593–616.
5. Fiebig HH, Dengler WA, Roth T. Human tumor xenografts: predictivity, characterization, and discovery of new-anticancer agents. In: Fiebig HH, Burger AM, editors. Relevance of tumor models for anti-cancer drug development. Contrib Oncol, Vol 54, Basel: Karger; 1999. p. 29–50.